Skin WoundNCT05984628
Umbilical Cord Stem Cells for Skin Grafts in Donor Site Wounds
A study testing human umbilical cord mesenchymal stem cells and blank solvent in people with Skin Wound and Scar, Hypertrophic, run by Fujian Medical University Union Hospital at 1 site in China.
Trial summary
The goal of this clinical trial is to evaluate the safety and effectiveness of human umbilical cord mesenchymal stem cell (hUCMSC) therapy in patients undergoing medium-thickness skin grafts for donor site wounds. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Skin Wound, Scar, Hypertrophic
- What is being tested?
- human umbilical cord mesenchymal stem cells and blank solvent
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 88 participants
- Where
- 1 siteChina
- Study dates
- 20 Oct 2021to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Patients between 18 and 60 years old with extensive scars, large benign tumors, or fresh wounds on the body surface.
- Patients who undergo medium-thickness skin graft surgery (donor site can be from the thigh, abdomen, or back).
- Participants who have a thorough understanding of the study objectives, significance, implementation plan, potential benefits, risks involved, measures to address risks, and the rights and obligations of the subjects (including privacy protection and the right to withdraw), and are willing to participate in this clinical study and can cooperate effectively.
Who cannot join
- Participants who meet any of the following criteria are not suitable for inclusion:
- Hypertension, hypotension, heart disease (including history of myocardial ischemia, coronary heart disease, myocarditis).
- Liver or kidney dysfunction.
- Infectious diseases (including viral hepatitis, syphilis, HIV/AIDS, etc.).
- Venous thrombosis, thoracic or abdominal aortic aneurysm, aortic dissection.
- Blood disorders (abnormal coagulation function, anemia, leukemia, polycythemia vera, aplastic anemia, etc.).
Show all 21Show fewer
- Allergic conditions (urticaria, bronchial asthma, history of allergic reactions to two or more drugs or foods).
- Respiratory system diseases (chronic bronchitis, emphysema, bronchiectasis, respiratory failure, chronic obstructive pulmonary disease, interstitial pneumonia).
- Digestive system diseases (severe gastric or duodenal ulcers, chronic gastritis, chronic pancreatitis).
- Urinary system diseases (chronic urinary tract infections, nephritis, nephrotic syndrome).
- Endocrine system diseases (hyperthyroidism, diabetes, acromegaly, pituitary diseases, adrenal diseases, diabetes insipidus).
- Organic neurological disorders or psychiatric illnesses (encephalitis, sequelae of traumatic brain injury, epilepsy, schizophrenia, hysteria, depression, severe insomnia, neurasthenia).
- Chronic skin diseases (especially infectious, allergic, and inflammatory systemic skin diseases, such as extensive eczema, pemphigus, pemphigoid).
- Autoimmune diseases and collagen diseases (such as systemic lupus erythematosus, dermatomyositis, scleroderma).
- History of long-term smoking, alcohol abuse, or drug addiction.
- History of major surgeries (such as gastric, lung, splenic, renal, or liver resection).
- History of other significant malignant tumors.
- Blood donation or organ transplantation within the past 5 years.
- Pregnancy, lactation, menstrual period, or within 1 year after termination of pregnancy.
- Previous circumstances of being rejected for voluntary blood donation.
- Other situations deemed unsuitable for participation in this study by the investigators.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Chenxiaosong
Fujian, Fuzhou, 350001
xiaosong - chen, director, 13365910035, chenxiaosong74@163.com
About this study
The goal of this clinical trial is to evaluate the safety and effectiveness of human umbilical cord mesenchymal stem cell (hUCMSC) therapy in patients undergoing medium-thickness skin grafts for donor site wounds. The study aims to answer the following main questions:
- Question 1: Does hUCMSC therapy improve the healing quality and speed of donor site wounds in comparison to standard treatment?
- Question 2: Does hUCMSC therapy reduce scar formation in the donor site wounds?
Read more
Participants in this study will undergo medium-thickness skin grafts, and those in the treatment group will receive hUCMSC therapy. The main tasks for participants will involve regular follow-up visits, monitoring of wound healing progress, and assessment of any potential side effects or complications associated with the therapy.
In order to evaluate the effectiveness of hUCMSC therapy, researchers will compare the treatment group receiving hUCMSC therapy with a control group that receives standard treatment alone. The aim is to determine if the use of hUCMSC therapy leads to improved healing outcomes and reduced scar formation compared to the standard treatment group.
Read the detailed description
The donor site of the medium-thickness skin graft procedure usually forms scars or even hypertrophic scars, which significantly differ from normal skin physiology and cause discomfort to patients such as itching and burning sensations. Currently, the pathological mechanism of scar formation is not fully understood. There is a pressing clinical need for new methods to improve the healing quality and speed of donor site wounds in patients undergoing medium-thickness skin grafts and to reduce scar formation.
It is well known that various types of stem cells from different sources are involved in the process of wound repair. Under the regulation of various signaling molecules and chemotactic factors, they migrate to the wound, proliferate, and differentiate into various cellular components of the skin, thus constructing new tissue structures and achieving wound healing. Stem cells possess powerful self-renewal and multi-directional differentiation abilities. Some stem cells have been successfully applied in the treatment of severe burn wounds and non-healing wounds, yielding promising results.
Furthermore, in recent years, tissue engineering techniques have been used to combine stem cells with appropriate scaffolds to create tissue-engineered skin, utilizing the potential of stem cells for multi-directional differentiation and rapid expansion. This approach allows for rapid coverage and functional reconstruction of large-area wounds. Therefore, we also hope to enhance the healing quality of donor site wounds in patients undergoing medium-thickness skin grafts and inhibit excessive scar formation by utilizing stem cell technology.
Among the various options, the use of human umbilical cord mesenchymal stem cells (UCMSC) is highly feasible for treating donor site wounds in medium-thickness skin graft procedures. UCMSC has abundant sources, easy collection, easy expansion, no harm to donors, no ethical controversies, potential for industrialization and standardized clinical treatment, and excellent biological characteristics.
This study aims to investigate the safety and efficacy of human umbilical cord mesenchymal stem cell (hUCMSC) therapy for donor site wounds in medium-thickness skin grafts, as well as its effect in reducing scar formation.
- Conditions
- Skin Wound, Scar, Hypertrophic
- Being tested
- human umbilical cord mesenchymal stem cells, blank solvent
- Keywords
- hUCMSC, Skin Wound, Scar, Hypertrophic, Stem cell
- Medical subject headings
- Cicatrix, Hypertrophic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
human umbilical cord mesenchymal stem cellsProcedure or surgery
After the completion of the donor site harvesting in the experimental group, allogeneic umbilical cord mesenchymal stem cells are injected into the deep layer of the de-epithelialized area and the surrounding 0.5cm subcutaneous region. After the injection, the wound is covered and dressed with conventional dressings.
blank solventProcedure or surgery
After the completion of the donor site harvesting in the experimental group, the de-epithelialized area and the surrounding 0.5cm subcutaneous region is injected an equal volume of blank solvent for stem cell suspension in the control group. After the injection, the wound is covered and dressed with conventional dressings.
| Study group | Role | What they receive |
|---|---|---|
| human umbilical cord mesenchymal stem cells | Experimental | Injection of human umbilical cord mesenchymal stem cells (hUCMSC) into the donor site.
1. Dosage of stem cell preparation: Calculated based on the area of the donor site, with a cell count of 1X10^5cells/cm2.
2. Administration method: The cells are prepared as an injectable suspension using a blank solvent for stem cells at a concentration of 1X10^6 cells/ml (0.1 ml/cm2).
3. Timing of administration: Administered immediately after completion of the donor site harvesting procedure.
4. Treatment duration: The stem cell administration is a single dose, administered at the specified timing as described above Receives: Procedure: human umbilical cord mesenchymal stem cells |
| blank solvent | Placebo comparator | Injection of an equal volume of blank solvent for suspension of stem cells into the donor site.
1. Dosage of Control group preparation: Calculated based on the area of the donor site.
2. Administration method: Injection of an equal volume of blank solvent for suspension of stem cells into the donor site.
3. Timing of administration: Administered immediately after completion of the donor site harvesting procedure.
4. Treatment duration: The Control group administration is a single dose, administered at the specified timing as described above Receives: Procedure: blank solvent |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to epithelialization of the skin wound
Record the size of the donor site wound at each follow-up time point and document it with photographs.
Measured: 12 months
Observation of scar formation
Record the height and erythema of the donor site scar at each follow-up time point and document them with photographs.
It will be assessed using, Vancouver scar scale at time of presentation and at 12 months after the intervention. Pre and post intervention ratings will be compared and percentage increase or decrease in the rating will be documented. Vancouver Scar Scale is a 13 points scale and includes four parameters, pigmentation, vascularity pliability and height of scar.13 It is an objective scale and examining doctor will assess and record score out of 13. Lesser the score better is the scar
Measured: 12 months
Secondary outcomes (2)
Itching at wound site
It will be assessed at the time of presentation and at 12 months after the intervention using severity of pruritus scale. It is 4 point rating scale from 0 (no itch) to 3(severe itch disturbing the sleep) assessing severity of pruritus within 24-hours recall period. Pre and post intervention ratings will be compared and percentage increase or decrease in the rating will be documented.
Measured: 12 months
Pain At scar Site
Patient will be asked to rate his/her current, best and worst pain level over past 24 hours on scale of 0 (no pain) to 10 (worst pain imaginable). Pain at scar site will be assessed at time of presentation and then at 12 months after start of the treatment. Pre and post intervention ratings will be compared and percentage increase or decrease in the rating will be documented. This scale is chosen due to its high feasibility and good compliance.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2023
- Study start20 Oct 2021
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Skin WoundStudies of the same condition, open and under way.
- More trials run by Fujian Medical University Union HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 88 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fujian Medical University Union Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, ChenXiaosong, Fujian Medical University Union Hospital
- Investigators
- xiaosong xiaosong, xiaosong, Study chair, Affiliated Union Hospital of Fujian Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05984628
- Sponsor's protocol ID
- 2020GXB001-01
- Status last verified
- Sep 2026
- First submitted
- 14 Jul 2023
- Last updated
- 3 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Umbilical Cord Stem Cells for Skin Grafts in Donor Site Wounds
- ClinicalTrials.gov ID
- NCT05984628
- Acronym / sponsor ID
- 2020GXB001-01
- Conditions
- Skin Wound, Scar, Hypertrophic
- Keywords
- hUCMSC, Skin Wound, Scar, Hypertrophic, Stem cell
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 88 participants (estimated)
- Lead sponsor
- Fujian Medical University Union HospitalUniversity, hospital or other
- Study start
- 20 Oct 2021 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 9 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the safety and effectiveness of human umbilical cord mesenchymal stem cell (hUCMSC) therapy in patients undergoing medium-thickness skin grafts for donor site wounds. The study aims to answer the following main questions:
- Question 1: Does hUCMSC therapy improve the healing quality and speed of donor site wounds in comparison to standard treatment?
- Question 2: Does hUCMSC therapy reduce scar formation in the donor site wounds?
Participants in this study will undergo medium-thickness skin grafts, and those in the treatment group will receive hUCMSC therapy. The main tasks for participants will involve regular follow-up visits, monitoring of wound healing progress, and assessment of any potential side effects or complications associated with the therapy.
In order to evaluate the effectiveness of hUCMSC therapy, researchers will compare the treatment group receiving hUCMSC therapy with a control group that receives standard treatment alone. The aim is to determine if the use of hUCMSC therapy leads to improved healing outcomes and reduced scar formation compared to the standard treatment group.
Detailed description
The donor site of the medium-thickness skin graft procedure usually forms scars or even hypertrophic scars, which significantly differ from normal skin physiology and cause discomfort to patients such as itching and burning sensations. Currently, the pathological mechanism of scar formation is not fully understood. There is a pressing clinical need for new methods to improve the healing quality and speed of donor site wounds in patients undergoing medium-thickness skin grafts and to reduce scar formation.
It is well known that various types of stem cells from different sources are involved in the process of wound repair. Under the regulation of various signaling molecules and chemotactic factors, they migrate to the wound, proliferate, and differentiate into various cellular components of the skin, thus constructing new tissue structures and achieving wound healing. Stem cells possess powerful self-renewal and multi-directional differentiation abilities. Some stem cells have been successfully applied in the treatment of severe burn wounds and non-healing wounds, yielding promising results.
Furthermore, in recent years, tissue engineering techniques have been used to combine stem cells with appropriate scaffolds to create tissue-engineered skin, utilizing the potential of stem cells for multi-directional differentiation and rapid expansion. This approach allows for rapid coverage and functional reconstruction of large-area wounds. Therefore, we also hope to enhance the healing quality of donor site wounds in patients undergoing medium-thickness skin grafts and inhibit excessive scar formation by utilizing stem cell technology.
Among the various options, the use of human umbilical cord mesenchymal stem cells (UCMSC) is highly feasible for treating donor site wounds in medium-thickness skin graft procedures. UCMSC has abundant sources, easy collection, easy expansion, no harm to donors, no ethical controversies, potential for industrialization and standardized clinical treatment, and excellent biological characteristics.
This study aims to investigate the safety and efficacy of human umbilical cord mesenchymal stem cell (hUCMSC) therapy for donor site wounds in medium-thickness skin grafts, as well as its effect in reducing scar formation.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| human umbilical cord mesenchymal stem cells | Experimental | Procedure: human umbilical cord mesenchymal stem cellsInjection of human umbilical cord mesenchymal stem cells (hUCMSC) into the donor site. 1. Dosage of stem cell preparation: Calculated based on the area of the donor site, with a cell count of 1X10^5cells/cm2. 2. Administration method: The cells are prepared as an injectable suspension using a blank solvent for stem cells at a concentration of 1X10^6 cells/ml (0.1 ml/cm2). 3. Timing of administration: Administered immediately after completion of the donor site harvesting procedure. 4. Treatment duration: The stem cell administration is a single dose, administered at the specified timing as described above |
| blank solvent | Placebo comparator | Procedure: blank solventInjection of an equal volume of blank solvent for suspension of stem cells into the donor site. 1. Dosage of Control group preparation: Calculated based on the area of the donor site. 2. Administration method: Injection of an equal volume of blank solvent for suspension of stem cells into the donor site. 3. Timing of administration: Administered immediately after completion of the donor site harvesting procedure. 4. Treatment duration: The Control group administration is a single dose, administered at the specified timing as described above |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Patients between 18 and 60 years old with extensive scars, large benign tumors, or fresh wounds on the body surface.
- Patients who undergo medium-thickness skin graft surgery (donor site can be from the thigh, abdomen, or back).
- Participants who have a thorough understanding of the study objectives, significance, implementation plan, potential benefits, risks involved, measures to address risks, and the rights and obligations of the subjects (including privacy protection and the right to withdraw), and are willing to participate in this clinical study and can cooperate effectively.
Key exclusion criteria (21 listed)
- Hypertension, hypotension, heart disease (including history of myocardial ischemia, coronary heart disease, myocarditis).
- Liver or kidney dysfunction.
- Infectious diseases (including viral hepatitis, syphilis, HIV/AIDS, etc.).
- Venous thrombosis, thoracic or abdominal aortic aneurysm, aortic dissection.
- Blood disorders (abnormal coagulation function, anemia, leukemia, polycythemia vera, aplastic anemia, etc.).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| human umbilical cord mesenchymal stem cellsAfter the completion of the donor site harvesting in the experimental group, allogeneic umbilical cord mesenchymal stem cells are injected into the deep layer of the de-epithelialized area and the surrounding 0.5cm subcutaneous region. After the injection, the wound is covered and dressed with conventional dressings. | Procedure or surgery | human umbilical cord mesenchymal stem cells |
| blank solventAfter the completion of the donor site harvesting in the experimental group, the de-epithelialized area and the surrounding 0.5cm subcutaneous region is injected an equal volume of blank solvent for stem cell suspension in the control group. After the injection, the wound is covered and dressed with conventional dressings. | Procedure or surgery | blank solvent |
Primary outcome
Time to epithelialization of the skin wound
Time frame: 12 months
Record the size of the donor site wound at each follow-up time point and document it with photographs.
Observation of scar formation
Time frame: 12 months
Record the height and erythema of the donor site scar at each follow-up time point and document them with photographs. It will be assessed using, Vancouver scar scale at time of presentation and at 12 months after the intervention. Pre and post intervention ratings will be compared and percentage increase or decrease in the rating will be documented. Vancouver Scar Scale is a 13 points scale and includes four parameters, pigmentation, vascularity pliability and height of scar.13 It is an objective scale and examining doctor will assess and record score out of 13. Lesser the score better is the scar
2 secondary outcomes
Itching at wound site
Time frame: 12 months
Pain At scar Site
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2026.
Related trials for Skin Wound
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Not yet recruiting
Safety Study of Microlyte DualGuard
Wound Closure, Wound Care
Active, not recruiting
Evaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics
Foot, Diabetic
Recruiting
Efficacy and Safety of ZKARE® Gel and Its Accessory ZKAPI® in the Treatment of Chronic Ulcers.
Chronic Ulcers
RecruitingObservational study
3D Versus 2D Strain Echocardiography for Early Detection of Cardiotoxicity During Cancer Therapy
Cancer Related Cardiovascular Toxicity, Anthracycline Related Cardiotoxicity in Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
xiaosong xiaosong, xiaosong study chair
Affiliated Union Hospital of Fujian Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing human umbilical cord mesenchymal stem cells and blank solvent in people with Skin Wound and Scar, Hypertrophic, run by Fujian Medical University Union Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact xiaosong - chen, director (13365910035, chenxiaosong74@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to epithelialization of the skin wound (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.